ABSTRACT
No disponible
Subject(s)
Humans , Cardiac Surgical Procedures , Methicillin-Resistant Staphylococcus aureus , Staphylococcal Infections/drug therapy , Delivery of Health Care , Mupirocin , Operating Rooms , Staphylococcus aureusABSTRACT
Las infecciones de partes blandas son un importante problema de salud, con una incidencia creciente y una mortalidad elevada. El aumento de su incidencia se debe al incremento de la población de riesgo (especialmente sujetos inmunodeprimidos), al incremento de las resistencias bacterianas debido al uso inapropiado de antibióticos de amplio espectro y a la capacidad de los patógenos para adaptarse a ambientes nuevos. El tratamiento adecuado incluye un abordaje integral con una vigilancia epidemiológica estricta, el cumplimiento de las recomendaciones terapéuticas empíricas iniciales y un desbridamiento quirúrgico precoz cuando se estime necesario. El principal microorganismo causante de estas infecciones es Staphylococcus aureus. En los últimos años se han descrito múltiples casos por cepas de S. aureus resistentes a meticilina (SARM). En España, la incidencia global del SARM es del 29%, aunque hay series en las que llega hasta el 46,4%. Por este motivo, en la presente revisión se pone especial interés en este microorganismo (AU)
Soft tissue infections represent an emerging health problem with a growing incidence and mortality. The augmented incidence of skin and soft tissue infections is the result of a number of factors, such as the increase of immunocompromised patients, emergence of multidrug-resistant pathogens due to the irrational use of antibiotics and the ability of pathogens to adapt to the environment. Successful management requires a global performance that involves a surveillance program, appropriate empirical antibiotic therapy and prompt surgical exploration with extensive debridement of devitalized tissue. Staphylococcus aureus is the most common pathogen and, in the last few years, methicillin-resistant S. aureus (MRSA) has become commonplace. In Spain, the global incidence of MRSA is 29%; however, there are series in which rises to 46.4%. For this reason, MRSA will be highlighted in this revision (AU)
Subject(s)
Humans , Soft Tissue Infections/epidemiology , Cellulite/epidemiology , Erysipelas/epidemiology , Streptococcal Infections/epidemiology , Fasciitis, Necrotizing/epidemiology , Myositis/epidemiology , Pyomyositis/epidemiology , Methicillin-Resistant Staphylococcus aureus/pathogenicity , Risk FactorsABSTRACT
Soft tissue infections represent an emerging health problem with a growing incidence and mortality. The augmented incidence of skin and soft tissue infections is the result of a number of factors, such as the increase of immunocompromised patients, emergence of multidrug-resistant pathogens due to the irrational use of antibiotics and the ability of pathogens to adapt to the environment. Successful management requires a global performance that involves a surveillance program, appropriate empirical antibiotic therapy and prompt surgical exploration with extensive debridement of devitalized tissue. Staphylococcus aureus is the most common pathogen and, in the last few years, methicillin-resistant S. aureus (MRSA) has become commonplace. In Spain, the global incidence of MRSA is 29%; however, there are series in which rises to 46.4%. For this reason, MRSA will be highlighted in this revision.
